| scholarly article | Q13442814 |
| P50 | author | Elías Campo | Q5830202 |
| Erlend B. Smeland | Q17107612 | ||
| Hans Konrad Müller-Hermelink | Q19284834 | ||
| Elaine Jaffe | Q19647268 | ||
| Andreas Rosenwald | Q28379725 | ||
| Jan Delabie | Q28379730 | ||
| Itziar Salaverria | Q38319024 | ||
| Víctor Moreno | Q40183186 | ||
| Sílvia Beà | Q42886871 | ||
| Joseph M Connors | Q48364472 | ||
| Randy D Gascoyne | Q87831803 | ||
| Dennis D Weisenburger | Q87934333 | ||
| James O Armitage | Q87934469 | ||
| Wing C Chan | Q87934470 | ||
| Armando López-Guillermo | Q88697793 | ||
| Emili Montserrat | Q89370956 | ||
| Harald Holte | Q89524392 | ||
| Timothy Greiner | Q92884271 | ||
| Wyndham H. Wilson | Q110350523 | ||
| Rita M. Braziel | Q114521837 | ||
| Stein Kvaloy | Q114521848 | ||
| Lymphoma/Leukemia Molecular Profiling Project | Q114521867 | ||
| Andreas Zettl | Q117252455 | ||
| P2093 | author name string | John Powell | |
| Louis M Staudt | |||
| George Wright | |||
| Richard I Fisher | |||
| Richard Simon | |||
| Liming Yang | |||
| Thomas M Grogan | |||
| German Ott | |||
| Xavier Puig | |||
| Christof Burek | |||
| Philipp Jehn | |||
| P2860 | cites work | Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas | Q24652646 |
| Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma | Q24672476 | ||
| A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma | Q24680233 | ||
| The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma | Q27824784 | ||
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
| A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project | Q28239256 | ||
| Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors | Q34190883 | ||
| Signatures of the immune response | Q34376859 | ||
| BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma | Q35102934 | ||
| Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells | Q36369816 | ||
| Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. | Q40465454 | ||
| Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes | Q40514744 | ||
| The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis | Q40766945 | ||
| Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line | Q40821711 | ||
| Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas | Q45037157 | ||
| Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Mol | Q51027001 | ||
| Cytogenetic characterization of diffuse large cell lymphoma using multi-color fluorescence in situ hybridization. | Q52545343 | ||
| The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. | Q53931762 | ||
| Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. | Q54328994 | ||
| Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma | Q56915483 | ||
| Impact of DNA amplification on gene expression patterns in breast cancer | Q57274809 | ||
| bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma | Q69490670 | ||
| Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene | Q71017596 | ||
| DNA copy number changes in diffuse large B-cell lymphoma--comparative genomic hybridization study | Q71128052 | ||
| Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group | Q73168646 | ||
| Chromosomal imbalances in diffuse large B-cell lymphoma detected by comparative genomic hybridization | Q74615764 | ||
| Chromosomal and gene amplification in diffuse large B-cell lymphoma | Q74696857 | ||
| The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile | Q77768040 | ||
| Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma | Q77768111 | ||
| Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas | Q77780220 | ||
| Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics | Q95751079 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diffuse large B-cell lymphoma | Q2626074 |
| B-cell lymphoma | Q4833719 | ||
| P304 | page(s) | 3183-3190 | |
| P577 | publication date | 2005-07-26 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction | |
| P478 | volume | 106 |
| Q90459096 | "Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements |
| Q30485971 | A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphoma |
| Q28538467 | A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma |
| Q39077324 | A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. |
| Q34313461 | A tumour suppressor network relying on the polyamine-hypusine axis |
| Q27683708 | ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets |
| Q36274840 | ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans |
| Q47600079 | Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells |
| Q35023886 | Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues |
| Q38798801 | Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas |
| Q48338600 | Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings |
| Q38836263 | Antitumor activity of fucoidan against diffuse large B cell lymphoma in vitro and in vivo. |
| Q45973697 | Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. |
| Q38467195 | Array comparative genomic hybridization reveals a very high frequency of deletions of the long arm of chromosome 6 in testicular lymphoma. |
| Q39280908 | Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders |
| Q35051460 | Array-comparative genomic hybridization profiling of immunohistochemical subgroups of diffuse large B-cell lymphoma shows distinct genomic alterations |
| Q34339662 | BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma |
| Q34513460 | Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation |
| Q39313119 | CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma |
| Q38210047 | CNS lymphoma: a practical diagnostic approach |
| Q64229386 | CaDrA: A Computational Framework for Performing Candidate Driver Analyses Using Genomic Features |
| Q35206717 | Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo |
| Q33591789 | Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm |
| Q38466460 | Characterization of chromosomal aberrations in diffuse large B-cell lymphoma (DLBL) by G-banding and spectral karyotyping (SKY). |
| Q53620559 | Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma. |
| Q79252670 | Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach |
| Q45001810 | Chromosomal imbalances are associated with outcome of Helicobacter pylori eradication in t(11;18)(q21;q21) negative gastric mucosa-associated lymphoid tissue lymphomas |
| Q37553676 | Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas |
| Q35053072 | Clear cell variant of diffuse large B-cell lymphoma: a case report |
| Q37365459 | Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement |
| Q40415214 | Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival i |
| Q61906657 | Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas |
| Q41974323 | Construction and analysis of tree models for chromosomal classification of diffuse large B-cell lymphomas |
| Q34061974 | Copy number variation analysis on a non-Hodgkin lymphoma case-control study identifies an 11q25 duplication associated with diffuse large B-cell lymphoma |
| Q37132882 | Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma |
| Q37874219 | Cytomorphologic findings of B-cell lymphomas with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas). |
| Q37124632 | DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status |
| Q37121717 | Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course |
| Q36812163 | Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. |
| Q37545385 | Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice. |
| Q35119804 | Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma |
| Q81551267 | Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma |
| Q38138170 | Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features |
| Q53267924 | Diffuse large B-cell lymphoma cycling off the main track. |
| Q44483495 | Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. |
| Q36622610 | Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities |
| Q36629205 | Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma |
| Q40094003 | EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features |
| Q89551910 | Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes |
| Q36232304 | Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC |
| Q47130109 | Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1. |
| Q80670802 | Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma |
| Q42356327 | Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP |
| Q61445091 | Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis |
| Q36871999 | FOXP1: a potential therapeutic target in cancer. |
| Q80195197 | Fine-needle aspiration biopsy of non-Hodgkin lymphoma for use in expression microarray analysis |
| Q37900457 | From MALT lymphoma to the CBM signalosome: three decades of discovery |
| Q36192439 | Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. |
| Q21093284 | Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells |
| Q55042257 | Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. |
| Q61312181 | Gains ofREL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein |
| Q42502797 | Gene expression in 16q is associated with survival and differs between Sørlie breast cancer subtypes |
| Q36051184 | Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma |
| Q36799850 | Gene expression profiling in diffuse large B-cell lymphoma |
| Q104795172 | Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma |
| Q55041931 | Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. |
| Q37000308 | Genetics and epigenetics of 1q rearrangements in hematological malignancies. |
| Q31114440 | Genome Expression Pathway Analysis Tool--analysis and visualization of microarray gene expression data under genomic, proteomic and metabolic context |
| Q44644345 | Genome wide DNA-profiling of HIV-related B-cell lymphomas |
| Q95940670 | Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-Cell lymphoma |
| Q36464002 | Genomic platforms for cancer research: potential diagnostic and prognostic applications in clinical oncology |
| Q54546572 | Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. |
| Q38042513 | Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large B-cell lymphoma: a review of the literature |
| Q90029008 | Genomics of aggressive B-cell lymphoma |
| Q35440675 | Genotypic and phenotypic differences between nodal and extranodal diffuse large B-Cell lymphomas |
| Q35080097 | Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma |
| Q39444436 | Glycotranscriptome study reveals an enzymatic switch modulating glycosaminoglycan synthesis during B-cell development and activation |
| Q33560762 | Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France |
| Q38728592 | Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions |
| Q90101887 | Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy |
| Q35082512 | High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. |
| Q40316913 | High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. |
| Q45899999 | Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. |
| Q34314178 | IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas |
| Q35067195 | Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations |
| Q55476353 | Identification of Hub Genes and Key Pathways Associated with Two Subtypes of Diffuse Large B-Cell Lymphoma Based on Gene Expression Profiling via Integrated Bioinformatics. |
| Q54504858 | Identification of genes putatively involved in the pathogenesis of diffuse large B-cell lymphomas by integrative genomics. |
| Q88817489 | Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience |
| Q35007061 | In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells |
| Q24676965 | Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma |
| Q30519549 | Inherited genetic variation and overall survival following follicular lymphoma |
| Q35818443 | Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications |
| Q51490388 | Integrated profiling of diffuse large B-cell lymphoma with 7q gain. |
| Q48248047 | Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. |
| Q37187384 | Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. |
| Q34360414 | InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions |
| Q33389374 | Intravascular large B cell lymphoma in Taiwan: an Asian variant of non-germinal-center origin |
| Q38656983 | Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? |
| Q45349447 | Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome |
| Q30249007 | Lenalidomide for the treatment of B-cell lymphoma |
| Q42087653 | Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities |
| Q27853399 | Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma |
| Q35849831 | Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival |
| Q52885667 | MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. |
| Q38147318 | MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas |
| Q42213358 | MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma |
| Q33455313 | Model-based clustering of array CGH data |
| Q24652565 | Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways |
| Q24655591 | Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium |
| Q34577553 | Mutations in the NF-kappaB signaling pathway: implications for human disease |
| Q37216927 | NFAT1 transcription factor regulates cell cycle progression and cyclin E expression in B lymphocytes |
| Q26796428 | Next-generation prognostic assessment for diffuse large B-cell lymphoma |
| Q38132359 | Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance |
| Q36688835 | Non-Hodgkin's lymphoma as an exemplar of the effects of genetics and genomics |
| Q27304386 | Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review |
| Q42715153 | Novel lymphoid neoplasms--the borderland between diffuse large B-cell lymphoma and Burkitt's lymphoma |
| Q36697045 | Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo |
| Q80168679 | Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma |
| Q54365695 | Overview of Genetic Diagnosis in Cancer. |
| Q34539577 | PAK1 mediates resistance to PI3K inhibition in lymphomas. |
| Q48335504 | PDCD1LG2 (PD-L2) RNA in situ hybridization is a sensitive, specific, and practical marker of primary mediastinal large B-cell lymphoma. |
| Q37768080 | Pathogenesis of diffuse large B cell lymphoma |
| Q37403682 | Pathophysiology of retinal lymphoma |
| Q39914215 | Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response |
| Q45964536 | Pathway activation patterns in diffuse large B-cell lymphomas. |
| Q35543402 | Pathway-based analysis of the hidden genetic heterogeneities in cancers |
| Q46317781 | Performance comparison of Affymetrix SNP6.0 and cytogenetic 2.7M whole-genome microarrays in complex cancer samples |
| Q36950447 | Plasma-based testing as a new paradigm for clinical testing in hematologic diseases |
| Q85804046 | Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype |
| Q36780164 | Predicting the outcome in non-Hodgkin lymphoma with molecular markers |
| Q42205963 | Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly |
| Q37702820 | Primary Breast Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Transformation to Diffuse Large B-cell Lymphoma: A Case Report |
| Q38129351 | Primary lymphoma of the central nervous system--a diagnostic challenge |
| Q80492538 | Primary mediastinal B-cell lymphoma |
| Q35599811 | Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. |
| Q51901667 | Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. |
| Q36971217 | Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3 |
| Q37706051 | Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients. |
| Q48371974 | R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis |
| Q40975965 | Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma |
| Q35006744 | Refining tumor-associated aneuploidy through 'genomic recoding' of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas |
| Q38222875 | Relevance of miR-21 in HIV and non-HIV-related lymphomas. |
| Q36177932 | S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. |
| Q39457134 | Serum protein profiling in diffuse large B-cell lymphoma |
| Q35689767 | Smooth muscle actin and s100p on non germinal centre diffuse large B cell lymphoma are adverse prognostic factors: pilot study |
| Q37240803 | Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1. |
| Q27851546 | Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin |
| Q42881035 | Somatic mutations altering Tyr641 of EZH2 are rare in primary central nervous system lymphoma |
| Q36629194 | Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature |
| Q38267888 | Structural genomic alterations in primary mediastinal large B-cell lymphoma |
| Q33761796 | Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms |
| Q57447372 | The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells |
| Q34470339 | The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. |
| Q37084564 | The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib |
| Q38596354 | The Role of EBV in the Pathogenesis of Diffuse Large B Cell Lymphoma |
| Q91658641 | The Unsolved Puzzle of c-Rel in B Cell Lymphoma |
| Q34313320 | The biology of human lymphoid malignancies revealed by gene expression profiling. |
| Q35556506 | The c-Rel Transcription Factor in Development and Disease |
| Q50953796 | The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma. |
| Q37815142 | The molecular background of aggressive B cell lymphomas as a basis for targeted therapy |
| Q36612630 | The molecular biology of diffuse large B-cell lymphoma |
| Q35628884 | The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas |
| Q33896749 | The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo |
| Q42040698 | The potential of copy number gains and losses, detected by array-based comparative genomic hybridization, for computational differential diagnosis of B-cell lymphomas and genetic regions involved in lymphomagenesis |
| Q34047455 | The significance of FOXP1 in diffuse large B-cell lymphoma |
| Q37385810 | Toward a systems biology approach to investigate cellular networks in normal and malignant B cells |
| Q53622530 | Transformed diffuse large B-cell lymphomas with gains of the discontinuous 12q12-14 amplicon display concurrent deregulation of CDK2, CDK4 and GADD153 genes. |
| Q37141364 | USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma |
| Q37143660 | Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. |
| Q37636976 | Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. |
| Q33870491 | Virtual CGH: an integrative approach to predict genetic abnormalities from gene expression microarray data applied in lymphoma |
| Q36022544 | Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. |
| Q81399255 | [DNA-chips in the diagnosis of hematological malignancies] |
| Q79521802 | [Extranodal diffuse large B-cell lymphoma--an organotypic disease?] |
Search more.